Skip to main content

Table 3 Prediction of stability at 6 months from administration of anti-fibrotic drugs in univariate analysis

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

VariableOR (95% CI)P-value
Sex, Male0.64 (0.15–2.83)0.55
Age1.05 (0.96–1.14)0.24
Smokers1.27 (0.33–4.96)0.72
Pack-years smoking1.01 (0.99–1.03)0.59
BMI0.89 (0.74–1.08)0.22
% FVC (%)1.01 (0.98–1.04)0.61
% DLco (%)1.00 (0.95–1.04)0.83
PaO2 at rest (Torr)1.01 (0.94–1.09)0.71
Minimum SpO2 during 6MWT (%)1.06 (0.93–1.21)0.37
6MWT Distance (m)1.00 (0.99–1.01)0.80
SP-A (ng/mL)0.99 (0.98–1.01)0.30
SP-D (ng/mL)1.00 (1.00–1.00)0.64
KL-6 (U/mL)1.00 (1.00–1.00)0.65
Pirfenidone2.01 (0.62–6.99)0.23
Treatment history of anti-fibrotic drugs (n)0.69 (0.14–3.53)0.66
Change in SP-A in 3 months (%)0.89 (0.82–0.96)< 0.01
Change in SP-D in 3 months (%)0.98 (0.96–1.00)0.12
Change in KL-6 in 3 months (%)0.96 (0.92–0.99)< 0.01
Change in SP-A in 6 months (%)0.89 (0.84–0.95)< 0.01
Change in SP-D in 6 months (%)0.95 (0.92–0.99)< 0.01
Change in KL-6 in 6 months (%)0.93 (0.89–0.97)< 0.01
  1. OR odd’s ratio; BMI body mass index; FVC forced vital capacity; DLco diffusing capacity of the lung for carbon monoxide; PaO2 partial pressure of arterial oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6 min-walk test; SP surfactant protein; KL-6 Krebs von den Lungen-6